Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.61 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.61 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.61 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.61 |
| ▸ | P2RY6 | Q15077 | 10/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.59 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.59 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.58 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5566439 | 0.96 | SLC28A1 (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2984123 | 0.96 | SLC28A1 (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL5566443 | 0.96 | SLC28A1 (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL5561796 | 0.96 | SLC28A1 (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL5561799 | 0.96 | SLC28A1 (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL5561410 | 0.94 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL5561404 | 0.94 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL30475849 | 0.91 | SLC28A1 (0.69) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL5566800 | 0.90 | P2RY2 (0.53) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL15531958 | 0.89 | SLC28A1 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776838-B1 | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| US-7166581-B1 | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1491201-B1 | Methods of reducing toxicity of 5-fluorouracil with acylated pyrimidine nucleosides | WELLSTAT THERAPEUTICS CORP (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-0831849-A4 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | WELLSTAT THERAPEUTICS CORP (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6344447-B2 | ADMINISTERING MIXTURE OF NUCLEOSIDES; ANTICANCER AGENT | PRO-NEURON, INC. | 2002-02-05 | — | — | US | disclosed |
| US-20010025032-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | VON BORSTEL REID W (US) | 2001-09-27 | — | — | US | disclosed |
| EP-0594667-B1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO NEURON INC (US) | 2001-09-19 | — | — | EP | disclosed |
| US-5968914-A | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | PRO-NEURON, INC. (US) | 1999-10-19 | — | — | US | disclosed |
| US-5736531-A | ADMINISTERING TO TREAT AND PREVENT TOXICITY | PRO-NEURON, INC. (US) | 1998-04-07 | — | — | US | disclosed |
| EP-0831849-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040165-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0594667-A4 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO NEURON INC (US) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994026761-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| EP-0594667-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-05-04 | — | — | EP | disclosed |
| WO-1993001202-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1993-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025032-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | TYMP, NUDT1, UNG | SLC28A1 100/4885SLC28A2 113/4885SLC29A1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.